查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
NGS液态切片市场:现状分析与预测(2023年～2028年)
市场调查报告书
商品编码
1310442

NGS液态切片市场:现状分析与预测(2023年～2028年)

NGS-based liquid biopsy Market: Current Analysis and Forecast (2023-2028)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于全球医疗机构不断加强癌症意识计划，NGS液体活检市场预计将以16.8%的速度稳定增长。

按类型划分，市场分为套件、设备和服务。2022年，套件行业主导市场。下一代测序（NGS）液体活检市场的试剂盒部分在促进液体活检样本中生物标誌物的准确、高效检测方面发挥着关键作用。此外，套件的成本效益和低可用性是推动该细分市场增长的主要因素之一。

按最终用户划分，市场分为诊断实验室、医院、诊所等。其中，医院类别将在2022年占据市场主导地位。这主要是由于癌症病例数量的增加，而住院患者数量的增加是医院业务增长的主要驱动力。

为了更好地了解NGS液体活检行业的市场采用情况，市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、意大利、欧洲其他地区）、亚太地区（中国、日本）、印度以及亚太地区其他地区）以及世界其他地区。2022年，北美地区在全球NGS液体活检市场中占据最大市场占有率，占有率为42.2%。由于美国和加拿大等新兴国家在该地区的存在，NGS液体活检市场正在不断增长。此外，由于对癌症诊断（包括NGS液体活检）的需求不断增加，癌症发病率持续上升是该地区面临的一个主要问题。例如，根据 Globocan 2020 报告，2020 年北美报告了 250 万癌症病例。据报导，其中 699,274 人死亡。

目录

第1章 市场简介

  • 市场定义
  • 主要目的
  • 相关利益者
  • 限制事项

第2章 调查手法或前提

  • 调查流程
  • 调查手法
  • 受访者简介

第3章 市场摘要

第4章 摘要整理

第5章 COVID-19对NGS液态切片市场的影响

第6章 NGS液态切片市场收益, 2020-2028F

第7章 市场洞察:各类型

  • 套件
  • 设备
  • 服务

第8章 市场洞察:各终端用户

  • 诊断研究所
  • 医院
  • 诊所
  • 其他

第9章 市场洞察:各地区

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 全球其他地区

第10章 NGS液态切片市场动态

  • 推动市场要素
  • 市场课题
  • 影响分析

第11章 NGS液态切片市场机会

第12章 NGS液态切片市场趋势

第13章 需求面和供给面的分析

  • 需求面分析
  • 供给面分析

第14章 价值链分析

第15章 价格分析

第16章 竞争模式

  • 竞争情形
    • 波特的五力分析

第17章 企业简介

  • GENOMILL HEALTH OY
  • Avida Biomed
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc
  • QIAGEN
  • Biocept Inc.
  • Guardant Health, Inc.
  • Lucence Health Inc

第18章 免责声明

简介目录
Product Code: UMHE2118084

NGS technologies have revolutionized liquid biopsy by enabling the detection and analysis of genetic alterations, such as mutations, copy number variations, and chromosomal rearrangements, with high sensitivity and accuracy. This approach has gained considerable attention in oncology for cancer diagnosis, monitoring treatment response, detecting minimal residual disease, and identifying potential drug resistance mechanisms. The market for NGS-based liquid biopsy is mainly driven by the increasing prevalence of cancer worldwide, the need for personalized medicine approaches, and the growing demand for non-invasive and real-time monitoring of cancer progression. For instance, as per the World Health Organization (WHO), Cancer was one of the leading causes of death worldwide, killing nearly 10 million people in 2020.

The NGS-Based Liquid Biopsy Market is expected to grow at a steady rate of 16.8% owing to Growing Cancer Awareness Programs by Global Health Organizations. For instance, For instance, on 4th February World Cancer Day, World Cancer Day aims to prevent millions of deaths each year by raising awareness about cancer and encouraging governments and individuals around the world to take action against cancer.

Based on type, the market is segmented into kits, instruments, and services. The kits category dominated the market in 2022. The Kits segment in the next-generation sequencing (NGS) based liquid biopsy market plays a crucial role in facilitating the accurate and efficient detection of biomarkers in liquid biopsy samples. Further, the kits are cost-effective and are available at cheaper rates are among the major factors driving the growth of the segment.

On the basis of end-users, the market is categorized into diagnostic laboratories, hospitals, clinics, and others. Among these, the hospital's category held a dominating share of the market in 2022. This is mainly due to the rising number of cancer cases, along with the increasing hospitalization are the major factors responsible for the segmental growth of the hospitals.

For a better understanding of the market adoption of the NGS-based liquid biopsy industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North American region held the largest dominating market share in 2022 with a share of 42.2% in the global NGS-based liquid biopsy market. The market for NGS-based liquid biopsy is witnessing growth in the region due to the presence of developed countries such as the U.S. and Canada in the region. Further, the continuously rising cancer incidences are the major problem faced by the region owing to which the demand for cancer diagnostics increases including NGS-based liquid biopsies. For instance, as per the Globocan 2020 report, 2.5 million cancer cases were reported in 2020 in North America. Among them, 699,274 deaths were reported in the same year.

Some of the major players operating in the market include: GENOMILL HEALTH OY; Avida Biomed; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; F. Hoffmann-La Roche Ltd; Illumina, Inc; QIAGEN; Biocept Inc.; Guardant Health, Inc.; and Lucence Health Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the NGS BASED LIQUID BIOPSY Market
  • 2.2. Research Methodology of the NGS BASED LIQUID BIOPSY Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE NGS BASED LIQUID BIOPSY MARKET

6 NGS BASED LIQUID BIOPSY MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY TYPE

  • 7.1. Kits
  • 7.2. Instruments
  • 7.3. Services

8 MARKET INSIGHTS BY END-USER

  • 8.1. Diagnostic Laboratories
  • 8.2. Hospitals
  • 8.3. Clinics
  • 8.4. Others

9 MARKET INSIGHTS BY REGION

  • 9.1. North America
    • 9.1.1. U.S.
    • 9.1.2. Canada
    • 9.1.3. Rest of North America
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. U.K.
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Rest of Asia-Pacific
  • 9.4. Rest of World

10 NGS BASED LIQUID BIOPSY MARKET DYNAMICS

  • 10.1. Market Drivers
  • 10.2. Market Challenges
  • 10.3. Impact Analysis

11 NGS BASED LIQUID BIOPSY MARKET OPPORTUNITIES

12 NGS BASED LIQUID BIOPSY MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 13.1. Demand Side Analysis
  • 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 PRICING ANALYSIS

16 COMPETITIVE SCENARIO

  • 16.1. Competitive Landscape
    • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

  • 17.1. GENOMILL HEALTH OY
  • 17.2. Avida Biomed
  • 17.3. Thermo Fisher Scientific Inc.
  • 17.4. Agilent Technologies Inc.
  • 17.5. F. Hoffmann-La Roche Ltd
  • 17.6. Illumina, Inc
  • 17.7. QIAGEN
  • 17.8. Biocept Inc.
  • 17.9. Guardant Health, Inc.
  • 17.10. Lucence Health Inc

18 DISCLAIMER